Skip to content
Screener

BridgeBio Pharma BBIO Q1 2025 earnings

Reported April 29, 2025 · After market close

Revenue$116.6MBeat by $48.2M
EPS-$0.88Beat by $0.12
Revenue estimate$68.4M
EPS estimate-$1.00

Next report

Oct 28, 2026 (in 2 months)
Revenue estimate$267.3M
EPS estimate-$0.67

Financials

Q1 2025

Income statement

See full
Revenue$116.6M-44.8%
Gross profit$114.0M-45.9%
Operating income-$104.4M-30,529%
Net income-$169.6M-369%
EPS (diluted)-$0.88-340%

Balance sheet

See full
Cash & equivalents$542.7M+14.2%
Total debt$10.1M-97.7%
Total equity-$1.6B-57.1%
Total assets$881.6M+3.8%

Cash flow

See full
Operating cash flow-$199.2M+9.2%
CapEx--100%
Free cash flow-$199.2M+9.5%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$6.57B+15.3%
Enterprise value$6.04B+6.5%
P/S51.6×+25.5×

Profitability

See full
Gross margin95.4%-3.6pp
Operating margin-547.6%-1,667pp
Net margin-531.2%-4,816pp

Returns & leverage

See full
Current ratio4.6×-1.0×

FAQ

When did BridgeBio Pharma report Q1 2025 earnings?
BridgeBio Pharma (BBIO) reported Q1 2025 earnings on April 29, 2025 after market close.
What were BridgeBio Pharma's Q1 2025 revenue and EPS?
BridgeBio Pharma reported revenue of $116.6M and eps of $-0.88 for Q1 2025.
Did BridgeBio Pharma beat estimates in Q1 2025?
Revenue beat the consensus estimate of $68.4M by $48.2M. EPS beat the consensus estimate of $-1.00 by $0.12.
How did BridgeBio Pharma's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 44.8% from $211.1M a year earlier and eps declined 1660.0% from $-0.05.
Where can I find BridgeBio Pharma's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-060085) and the 10-Q periodic report (0000950170-25-060314) directly on SEC EDGAR. The filing index links above go to sec.gov.